What is OSSIO?
OSSIO specializes in the development of innovative bone healing solutions that utilize its unique OSSIOfiber® technology. Unlike traditional permanent metal hardware, OSSIO's implants are designed to support natural bone regeneration, eventually integrating into the patient's own anatomy. The company's product portfolio, which includes suture anchors, fixation nails, and hammertoe fixation systems, is specifically engineered to reduce the risks associated with permanent metal implants, such as long-term inflammation or secondary removal surgeries. By focusing on orthopedic surgeons and patient-centric recovery outcomes, OSSIO is carving out a significant niche in the multi-billion dollar orthopedic implant market, offering a superior, integrated healing experience that aligns with modern value-based care initiatives.
How much funding has OSSIO raised?
OSSIO has raised a total of $138.1M across 4 funding rounds:
Series A
$22M
Series C
$38.5M
Private Equity
$27.6M
Debt
$50M
Series A (2019): $22M, investors not publicly disclosed
Series C (2022): $38.5M led by MVM Partners
Private Equity (2024): $27.6M supported by Courage Capital Management, MVM Partners, OCV Partners, and Questa Capital
Debt (2026): $50M featuring Monroe Capital and Horizon Technology Finance
Key Investors in OSSIO
Monroe Capital
Monroe Capital is a premier private credit asset management firm that provides customized debt financing solutions to middle-market companies, supporting growth and recapitalization efforts.
Horizon Technology Finance
Horizon Technology Finance is a specialty finance company focused on providing structured debt and venture lending to development-stage companies in the technology and life sciences sectors.
MVM Partners
MVM Partners is a healthcare-focused investment firm that partners with management teams to drive growth in medical technology, pharmaceuticals, and digital health.
What's next for OSSIO?
With the successful closure of this latest financing round, OSSIO is poised to scale its manufacturing capabilities and expand its clinical footprint. The strategic focus will likely shift toward deepening market penetration among orthopedic surgeons and broadening the application of OSSIOfiber® across new surgical indications. As the company transitions from a high-growth development stage to a more mature commercial entity, the focus will remain on clinical validation and the long-term performance of its bio-integrative hardware. Investors are closely watching how OSSIO leverages this capital to navigate the competitive landscape of medical technology, particularly as the demand for minimally invasive and patient-friendly orthopedic solutions continues to rise globally.
See full OSSIO company page
